Insuline Medical Stock Current Valuation
| INSL Stock | ILS 230.00 0.00 0.00% |
Valuation analysis of Insuline Medical helps investors to measure Insuline Medical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Insuline Medical's price fluctuation is very steady at this time. Calculation of the real value of Insuline Medical is based on 3 months time horizon. Increasing Insuline Medical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Insuline Medical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Insuline Stock. However, Insuline Medical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 230.0 | Real 198.45 | Hype 230.0 | Naive 208.04 |
The real value of Insuline Stock, also known as its intrinsic value, is the underlying worth of Insuline Medical Company, which is reflected in its stock price. It is based on Insuline Medical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Insuline Medical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Insuline Medical helps investors to forecast how Insuline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Insuline Medical more accurately as focusing exclusively on Insuline Medical's fundamentals will not take into account other important factors: Insuline Medical Company Current Valuation Analysis
Insuline Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Insuline Medical has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The current valuation for all Israel stocks is 100.0% higher than that of the company.
Insuline Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insuline Medical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insuline Medical could also be used in its relative valuation, which is a method of valuing Insuline Medical by comparing valuation metrics of similar companies.Insuline Medical is currently under evaluation in current valuation category among its peers.
Insuline Fundamentals
| Price To Earning | (40.77) X | |||
| Revenue | 40 K | |||
| EBITDA | (6.82 M) | |||
| Net Income | (7.01 M) | |||
| Cash And Equivalents | 1.15 M | |||
| Cash Per Share | 2.86 X | |||
| Current Ratio | 0.98 X | |||
| Book Value Per Share | (0.16) X | |||
| Cash Flow From Operations | (7.68 M) | |||
| Earnings Per Share | (30.78) X | |||
| Number Of Employees | 26 | |||
| Beta | 1.79 | |||
| Market Capitalization | 36.33 M | |||
| Total Asset | 1.58 M | |||
| Retained Earnings | (158 M) | |||
| Working Capital | (1000 K) | |||
| Current Asset | 8 M | |||
| Current Liabilities | 9 M | |||
| Net Asset | 1.58 M |
About Insuline Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insuline Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insuline Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insuline Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Insuline Stock
Insuline Medical financial ratios help investors to determine whether Insuline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Insuline with respect to the benefits of owning Insuline Medical security.